Yoo C Kim1, Hans E Grossniklaus2, Henry F Edelhauser2, Mark R Prausnitz1. 1. School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States. 2. Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, United States.
Abstract
PURPOSE: This study tested the hypothesis that highly targeted intrastromal delivery of bevacizumab using coated microneedles allows dramatic dose sparing compared with subconjunctival and topical delivery for treatment of corneal neovascularization. METHODS: Stainless steel microneedles 400 μm in length were coated with bevacizumab. A silk suture was placed in the cornea approximately 1 mm from the limbus to induce corneal neovascularization in the eyes of New Zealand white rabbits that were divided into different groups: untreated, microneedle delivery, topical eye drop, and subconjunctival injection of bevacizumab. All drug treatments were initiated 4 days after suture placement and area of neovascularization was measured daily by digital photography for 18 days. RESULTS: Eyes treated once with 4.4 μg bevacizumab using microneedles reduced neovascularization compared with untreated eyes by 44% (day 18). Eyes treated once with 2500 μg bevacizumab using subconjunctival injection gave similar results to microneedle-treated eyes. Eyes treated once with 4.4 μg subconjunctival bevacizumab showed no significant effect compared with untreated eyes. Eyes treated with 52,500 μg bevacizumab by eye drops three times per day for 14 days reduced the neovascularization area compared with untreated eyes by 6% (day 18), which was significantly less effective than the single microneedle treatment. Visual exam and histological analysis showed no observable effect of microneedle treatment on corneal transparency or microanatomical structure. CONCLUSIONS: This study shows that microneedles can target drug delivery to corneal stroma in a minimally invasive way and demonstrates effective suppression of corneal neovascularization after suture-induced injury using a much lower dose compared with conventional methods. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: This study tested the hypothesis that highly targeted intrastromal delivery of bevacizumab using coated microneedles allows dramatic dose sparing compared with subconjunctival and topical delivery for treatment of corneal neovascularization. METHODS:Stainless steel microneedles 400 μm in length were coated with bevacizumab. A silk suture was placed in the cornea approximately 1 mm from the limbus to induce corneal neovascularization in the eyes of New Zealand white rabbits that were divided into different groups: untreated, microneedle delivery, topical eye drop, and subconjunctival injection of bevacizumab. All drug treatments were initiated 4 days after suture placement and area of neovascularization was measured daily by digital photography for 18 days. RESULTS: Eyes treated once with 4.4 μg bevacizumab using microneedles reduced neovascularization compared with untreated eyes by 44% (day 18). Eyes treated once with 2500 μg bevacizumab using subconjunctival injection gave similar results to microneedle-treated eyes. Eyes treated once with 4.4 μg subconjunctival bevacizumab showed no significant effect compared with untreated eyes. Eyes treated with 52,500 μg bevacizumab by eye drops three times per day for 14 days reduced the neovascularization area compared with untreated eyes by 6% (day 18), which was significantly less effective than the single microneedle treatment. Visual exam and histological analysis showed no observable effect of microneedle treatment on corneal transparency or microanatomical structure. CONCLUSIONS: This study shows that microneedles can target drug delivery to corneal stroma in a minimally invasive way and demonstrates effective suppression of corneal neovascularization after suture-induced injury using a much lower dose compared with conventional methods. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: James A Matriano; Michel Cormier; Juanita Johnson; Wendy A Young; Margaret Buttery; Kofi Nyam; Peter E Daddona Journal: Pharm Res Date: 2002-01 Impact factor: 4.200
Authors: Jason Jiang; Harvinder S Gill; Deepta Ghate; Bernard E McCarey; Samir R Patel; Henry F Edelhauser; Mark R Prausnitz Journal: Invest Ophthalmol Vis Sci Date: 2007-09 Impact factor: 4.799
Authors: Mike P Holzer; Kerry D Solomon; David T Vroman; Helga P Sandoval; Philippe Margaron; Terrance J Kasper; Craig E Crosson Journal: Invest Ophthalmol Vis Sci Date: 2003-07 Impact factor: 4.799
Authors: Apoorva Panda; V Anusha Matadh; Sarasija Suresh; H N Shivakumar; S Narasimha Murthy Journal: Drug Deliv Transl Res Date: 2021-02-24 Impact factor: 4.617
Authors: Jonathan C J Wei; Grant A Edwards; Darren J Martin; Han Huang; Michael L Crichton; Mark A F Kendall Journal: Sci Rep Date: 2017-11-21 Impact factor: 4.379
Authors: Henry T Hsueh; Yoo-Chun Kim; Ian Pitha; Matthew D Shin; Cynthia A Berlinicke; Renee Ti Chou; Elizabeth Kimball; Julie Schaub; Sarah Quillen; Kirby T Leo; Hyounkoo Han; Amy Xiao; Youngwook Kim; Matthew Appell; Usha Rai; HyeYoung Kwon; Patricia Kolodziejski; Laolu Ogunnaike; Nicole M Anders; Avelina Hemingway; Joan L Jefferys; Abhijit A Date; Charles Eberhart; Thomas V Johnson; Harry A Quigley; Donald J Zack; Justin Hanes; Laura M Ensign Journal: Pharmaceutics Date: 2021-05-01 Impact factor: 6.321